At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes. A 30-week Randomised, Double-blind, Double-dummy, Active-controlled, Parallel-group, Multi-centre and Multi-national Trial
In Brief
A Phase 3 clinical trial evaluating Semaglutide 0.5 mg, Semaglutide 1.0 mg, and 4 other interventions for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 868 participants across 67 sites in 7 countries.
Detailed Summary
This trial is conducted in Africa, Asia, Europe and South America. The aim of the trial is to compare the effect of once-weekly dosing of two dose levels of semaglutide versus sitagliptin 100 mg once-daily on glycaemic control after 30 weeks of treatment. Subjects will remain on their stable pre-trial metformin.
Study Details
Timeline
Interventions
Up to 0.5 mg semaglutide injected subcutaneously (s.c., under the skin) once-weekly (OW) for 30 weeks
Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 30 weeks
Sitagliptin placebo tablets taken once-daily for 30 weeks
100 mg sitagliptin tablets taken once-daily for 30 weeks
Semaglutide placebo (0.5 mg) injected subcutaneously once-weekly for 30 weeks
Semaglutide placebo (1.0 mg) injected subcutaneously once-weekly for 30 weeks